Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tore Bengtsson is the founder and chief scientific officer of Atrogi AB, which is continuing to develop the drug candidate, and he and a co-author have applied for patents related to the substances examined in the study
its specially treated to inhibit the growth of bacteria
It was initially studied in Phase 1 and Phase 2 trials demonstrating tolerability and promising weight-loss effects
data, filling a gap left by research focused on diabetic populations or using less comprehensive samples
Improved memory was observed in ApoE 4, whilst worsening memory performance was identified in ApoE 4 non-carriers
While originally developed for the treatment of Type II Diabetes, these medications have has been found to promote weight loss in people with and without diabetes
